Puma Biotechnology, Inc. (PBYI) stock
PBYINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 14/3019% below fair value
$7.22+0.08 (+1.12%)
Close on Nov 18, 2026Market cap $372.70MP/E 13.9Yield –
Puma Biotechnology price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Puma Biotechnology's price to book ratio was 3.0× on Nov 11, 2026, against 2.2× a year earlier. Over the last 5 years it ranged from 1.6× to 22.7×, with a median of 3.8×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 3.0× | +0.4 |
| 2025 | Dec 31, 2025 | 2.6× | +0.5 |
| 2024 | Dec 31, 2024 | 2.1× | −3.2 |
| 2023 | Dec 29, 2023 | 5.3× | −3.4 |
| 2022 | Dec 30, 2022 | 8.7× | +1.7 |
| 2021 | Oct 29, 2021 | 7.0× | −7.1 |
| 2020 | Oct 30, 2020 | 14.2× | −5.7 |
| 2019 | Dec 31, 2019 | 19.8× | +2.9 |
| 2018 | Dec 31, 2018 | 16.9× | −29.8 |
| 2017 | Dec 29, 2017 | 46.7× | +35.7 |
| 2016 | Dec 30, 2016 | 10.9× | +0.6 |
| 2015 | Dec 31, 2015 | 10.4× | −29.9 |
| 2014 | Dec 31, 2014 | 40.3× | +8.9 |
| 2013 | Dec 31, 2013 | 31.3× | −10.4 |
| 2012 | Dec 31, 2012 | 41.7× | – |
See a number that looks wrong?